Neues von der CH-Virenfront...Schlieren ist so eine Art Silicon-Valley für Biotechs in der CH. Besonders Roche/Novartis greifen dort oft zu um sich auszubreiten.
ISSUER: CUREVAC N.V. TICKER: CVAC SECTOR: BIOTECHNOLOGY COUNTRY: GERMANY OFFER TYPE: INITIAL PUBLIC OFFERING (100% PRIMARY) LISTING VENUE: NASDAQ OFFER SIZE: $200M USD – AT MIDPOINT OF RANGE (EXCLUDING 15% GREENSHOE) SHARES: 13,333,333 OFFER PRICE: $14.00 - $16.00 PER SHARE IMPLIED MARKET CAP: $2,679M USD – AT MIDPOINT OF RANGE SHARE TYPE: COMMON SHARES OVER-ALLOTMENT OPTION: 15%
USE OF PROCEEDS:
TO ADVANCE LEAD ONCOLOGY PROGRAM, CV8102, THROUGH PHASE 2, ADVANCE LEAD VACCINE PROGRAM, CV7202, THROUGH PHASE 2, FUND DEVELOPMENT OF SARS-COV-2 PROGRAM THROUGH PHASE 2, ADVANCE OTHER PROGRAMS, EXPAND MANUFACTURING CAPABILITIES, WORKING CAPITAL AND GENERAL CORPORATE PURPOSES
BOOKRUNNER(S):
BOFA SECURITES, JEFFERIES, CREDIT SUISSE, BERENBERG, KEMPEN & CO
"... today announced the pricing of the previously announced offering of 30,675,000 shares of its common stock at a price to the public of $10.25 per share. Plug Power has granted the underwriters a 30-day option to purchase up to an additional 4,601,250 shares at the public offering price, less the underwriting discount....
